China NMPA Drug Inspection - Tianjin Lisheng Pharmaceutical Co., Ltd. - Hydrochlorothiazide tablets
China NMPA drug inspection for Tianjin Lisheng Pharmaceutical Co., Ltd. published June 20, 2020. Drug: Hydrochlorothiazide tablets. The Ningxia Hui Autonomous Region Drug Administration released Announcement No. 45 on June 20, 2020, detailing the resul
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Tianjin Lisheng Pharmaceutical Co., Ltd. published June 20, 2020. Drug: Hydrochlorothiazide tablets. The Ningxia Hui Autonomous Region Drug Administration released Announcement No. 45 on June 20, 2020, detailing the resul
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox